| Title |
Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty
|
|---|---|
| Published in |
Current Hematologic Malignancy Reports, July 2018
|
| DOI | 10.1007/s11899-018-0461-y |
| Pubmed ID | |
| Authors |
Talal Hilal, Jeffrey A. Betcher, Jose F. Leis |
| Abstract |
Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices. The cost of therapy for CLL has increased substantially since the introduction of oral therapies. This increase in cost is caused by multiple factors including cost of drug development, alternate reimbursement patterns, lack of transparency, and lack of free market competition. Oral therapies for CLL have dramatically increased costs for both patients and payers. Some solutions to overcome this include value-based pricing, transparency, and legal action that allow Medicare to negotiate drug prices with manufacturers. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 60% |
| China | 1 | 20% |
| United Kingdom | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Practitioners (doctors, other healthcare professionals) | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 20% |
| Other | 7 | 14% |
| Researcher | 6 | 12% |
| Student > Ph. D. Student | 3 | 6% |
| Librarian | 2 | 4% |
| Other | 8 | 16% |
| Unknown | 13 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 10% |
| Biochemistry, Genetics and Molecular Biology | 5 | 10% |
| Economics, Econometrics and Finance | 4 | 8% |
| Agricultural and Biological Sciences | 2 | 4% |
| Other | 4 | 8% |
| Unknown | 15 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 July 2018.
All research outputs
#14,058,790
of 24,046,191 outputs
Outputs from Current Hematologic Malignancy Reports
#236
of 438 outputs
Outputs of similar age
#168,133
of 331,288 outputs
Outputs of similar age from Current Hematologic Malignancy Reports
#11
of 13 outputs
Altmetric has tracked 24,046,191 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 438 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,288 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.